Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telaprevir rollover study for prior nonresponders from VX06-950-106 control group
NL-OMON30821Phase 2Not yet recruiting
- Sponsor
- Vertex Pharmaceuticals
- Start
- Aug 2007
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of telaprevir, interferon alfa and ribavirin in hepatitis C virus infection, sponsored by Vertex Pharmaceuticals. Primary endpoints: Access to telaprevir-based treatment, Safety and 2 more. Planned start Aug 2007; status: not yet recruiting.
02
Drugs
telaprevirinterferon alfaribavirin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on NL-OMON30821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON30821.